Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC

Experts share high-level results from the investigation of cretostimogene grenadenorepvec, an investigational targeted immunotherapy delivered intravesically for the treatment of non–muscle-invasive bladder cancer (NMIBC).

Video Player is loading.

Play Video

Play

Mute

Current Time 0:00

/

Duration 0:00

Loaded: 0%

0:00

Stream Type LIVE

Seek to live, currently behind liveLIVE

Remaining Time -0:00

 

1x

Playback Rate

Chapters

• Chapters

Descriptions

• descriptions off, selected

Captions

• captions settings, opens captions settings dialog
• captions off, selected

Audio Track

Fullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

Text

ColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-Transparent

Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparent

Window

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque

Font Size

50%75%100%125%150%175%200%300%400%

Text Edge Style

NoneRaisedDepressedUniformDropshadow

Font Family

Proportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps

Reset restore all settings to the default valuesDone

Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

EP: 1.Standard of Care and Intravesical Chemotherapy in NMIBC

EP: 2.BCG for treatment of NMIBC

EP: 3.Cystectomy in NMIBC

EP: 4.New Intravesical Delivery Systems and TAR-200 in NMIBC

EP: 5.TAR-200 Efficacy and Safety in High-Risk BCG- Unresponsive NMIBC (SunRISe-1)

EP: 6.TAR-200 Clinical Development Program in NMIBC

EP: 7.Other Investigational Drug Delivery Systems in NMIBC

Now Viewing

EP: 8.Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC

EP: 9.FDA-Approved Treatments for BCG-Unresponsive NMIBC

EP: 10.Use and Sequencing of Novel Treatments in NMIBC

EP: 11.Communication of Treatment Options for High-Risk NMIBC

EP: 12.Checkpoint Inhibitors for Treatment of NMIBC

EP: 13.Unmet Needs in NMIBC

EP: 14.Operationalizing TAR-200 and Other Delivery Systems in Practice

EP: 15.Patient Communication and Treatment Adherence in NMIBC

EP: 16.Uptake of New Treatments in Urology Practice

EP: 17.Final Thoughts and Clinical Trials in NMIBC

Video content above is prompted by the following:

• Cretostimogene grenadenorepvec is an investigational targeted immunotherapy that is delivered intravesically. Can you share high-level results with from it?
  

Related Videos

Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT

Treatment or Lack of Treatment of Small Renal Masses

The current treatment landscape of mHSPC

Strengths and Weaknesses of Imaging Modalities in ccRCC

BPH: Strategies for Guiding Patients From Medication to Intervention

Representation of Black men with mHSPC in clinical trials

Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses

Non–Muscle Invasive-Bladder Cancer Overview

NMIBC Maintenance Therapy: Timing, Dosing, and Follow-Up

BRCA Mutations in mHSPC: Impact on Therapy Selection